Pub Date : 2023-06-01DOI: 10.1136/gutjnl-2023-IDDF.196
A. Higashimori, Natsumi Naeda, M. Nakatani, Ikki Yamamoto, Tsuyoshi Yanagida, Daiyu Kin, K. Morimoto, E. Sasaki, T. Fukuda, Tesuo Arakawa, Y. Fujiwara
IDDF-2023-ABS-0156 Table 1Association between Tolerance of BP for index colonoscopy and surveillance rateTolerance of BP for index colonoscopy Surveillance rate% (n/N) Total 67% (127/186) 1. Very intolerable 47% (9/19) 2. Intolerable 48% (10/21) 3. Neither tolerable nor intolerable 76% (55/72) 4. Tolerable 71% (22/31) 5. Very tolerable 72% (31/43) P for trend test 0.04 IDDF2023-ABS-0156 Table 2Risk factors of non-compliance of surveillance colonoscopy by multivariate regression analysis Multivariate OR (95%CI) p value Age,/1-year increase 1.04 (1.03-1.05) 0.001 Male sex 1.13 (0.85-1.52) 0.40 BMI,/1-kg/m2 increase 1.05 (0.96-1.15) 0.28 Family history of CRC 0.93 (0.16-5.25) 0.92 Low education 0.92 (0.39-2.15) 0.90 Comorbidities 1.05 (0.51-2.13) 0.90 Low tolerance of BP for colonoscopy 2.45 (1.11-5.41) 0.006 Absence of primary care physician 4.63 (1.60-13.4) 0.001 BMI: body mass index, CRC: colorectal cancer, BP: bowel preparation IDDF2023-ABS-0156 Table 3The reasons of non-compliance surveillance colonoscopyReasons of non-compliance surveillance colonoscopy n, (%) Total 62 (100%) Not knowing about follow-up intervals 4 (6%) Having no symptoms 15 (24%) Fear of examination Pain during colonoscopy 1 (2%) Embarrassment during colonoscopy 0 (0%) Bowel preparation for colonoscopy 17 (28%) Over sedation during colonoscopy 2 (3%) Old age/severe illness for surveillance 10 (16%) Having no time 10 (16%) Having no money 1 (2%) Fear of Covid-19 infection 2 (3%) IDDF2023-ABS-0156 Figure 1ConclusionsOur findings highlight the need for improvement of the surveillance colonoscopy rate, especially for patients who had poor tolerance to BP on index colonoscopy and no gastroenterology visit. Providing a well-tolerated BP regimen may lead to an increase in surveillance colonoscopy compliance.
{"title":"IDDF2023-ABS-0156 Poor tolerance of bowel preparation for index colonoscopy decreases surveillance rate in high-risk adenoma removal patients","authors":"A. Higashimori, Natsumi Naeda, M. Nakatani, Ikki Yamamoto, Tsuyoshi Yanagida, Daiyu Kin, K. Morimoto, E. Sasaki, T. Fukuda, Tesuo Arakawa, Y. Fujiwara","doi":"10.1136/gutjnl-2023-IDDF.196","DOIUrl":"https://doi.org/10.1136/gutjnl-2023-IDDF.196","url":null,"abstract":"IDDF-2023-ABS-0156 Table 1Association between Tolerance of BP for index colonoscopy and surveillance rateTolerance of BP for index colonoscopy Surveillance rate% (n/N) Total 67% (127/186) 1. Very intolerable 47% (9/19) 2. Intolerable 48% (10/21) 3. Neither tolerable nor intolerable 76% (55/72) 4. Tolerable 71% (22/31) 5. Very tolerable 72% (31/43) P for trend test 0.04 IDDF2023-ABS-0156 Table 2Risk factors of non-compliance of surveillance colonoscopy by multivariate regression analysis Multivariate OR (95%CI) p value Age,/1-year increase 1.04 (1.03-1.05) 0.001 Male sex 1.13 (0.85-1.52) 0.40 BMI,/1-kg/m2 increase 1.05 (0.96-1.15) 0.28 Family history of CRC 0.93 (0.16-5.25) 0.92 Low education 0.92 (0.39-2.15) 0.90 Comorbidities 1.05 (0.51-2.13) 0.90 Low tolerance of BP for colonoscopy 2.45 (1.11-5.41) 0.006 Absence of primary care physician 4.63 (1.60-13.4) 0.001 BMI: body mass index, CRC: colorectal cancer, BP: bowel preparation IDDF2023-ABS-0156 Table 3The reasons of non-compliance surveillance colonoscopyReasons of non-compliance surveillance colonoscopy n, (%) Total 62 (100%) Not knowing about follow-up intervals 4 (6%) Having no symptoms 15 (24%) Fear of examination Pain during colonoscopy 1 (2%) Embarrassment during colonoscopy 0 (0%) Bowel preparation for colonoscopy 17 (28%) Over sedation during colonoscopy 2 (3%) Old age/severe illness for surveillance 10 (16%) Having no time 10 (16%) Having no money 1 (2%) Fear of Covid-19 infection 2 (3%) IDDF2023-ABS-0156 Figure 1ConclusionsOur findings highlight the need for improvement of the surveillance colonoscopy rate, especially for patients who had poor tolerance to BP on index colonoscopy and no gastroenterology visit. Providing a well-tolerated BP regimen may lead to an increase in surveillance colonoscopy compliance.","PeriodicalId":10401,"journal":{"name":"Clinical Gastroenterology","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77869279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.1136/gutjnl-2023-IDDF.165
Chenyue Xu, Fang Xu
IDDF2023-ABS-0032 Figure 1 IDDF2023-ABS-0032 Figure 2 IDDF2023-ABS-0032 Figure 3 IDDF2023-ABS-0032 Figure 4COVID-19 outcomes in moderate-severe vs mild or quiescent IBD[Figure omitted. See PDF]ConclusionsPatients with IBD, particularly UC had an increased risk of developing severe COVID-19. Active IBD is associated with adverse COVID-19 outcomes, and the risk is increased with the disease activity of IBD.
{"title":"IDDF2023-ABS-0032 Active inflammatory bowel disease is associated with severe covid-19: a systematic review and meta-analysis","authors":"Chenyue Xu, Fang Xu","doi":"10.1136/gutjnl-2023-IDDF.165","DOIUrl":"https://doi.org/10.1136/gutjnl-2023-IDDF.165","url":null,"abstract":"IDDF2023-ABS-0032 Figure 1 IDDF2023-ABS-0032 Figure 2 IDDF2023-ABS-0032 Figure 3 IDDF2023-ABS-0032 Figure 4COVID-19 outcomes in moderate-severe vs mild or quiescent IBD[Figure omitted. See PDF]ConclusionsPatients with IBD, particularly UC had an increased risk of developing severe COVID-19. Active IBD is associated with adverse COVID-19 outcomes, and the risk is increased with the disease activity of IBD.","PeriodicalId":10401,"journal":{"name":"Clinical Gastroenterology","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75191569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.1136/gutjnl-2023-iddf.209
Xiaolu Li, Rong Cao, Fangfei Xiao, Lin Ye, Xufei Wang, Yizhong Wang
Background
To evaluate the clinical characteristics and the molecular pathogenesis of C. difficile.
Methods
A total of 51 strains of C. difficile were collected from our hospital from 2014.10 to 2022.8. MICs for each strain against 11 antimicrobial agents were detected by the agar dilution method. Whole gene sequencing was performed on Illumina’s next-generation sequencing platform for 36 C. difficile strains.
Results
51 strains were isolated from 250 fecal samples. 44 strains were toxicogenic, and the detection rate of toxin A+B+ was 100%. Antimicrobial susceptibility testing showed that all isolates were sensitive to rifaximin. The resistance rates of rifampicin and vancomycin were low. All strains were resistant to ceftriaxone, ceftazidime and clindamycin, followed by erythromycin (84.31%), tetracycline, levofloxacin, metronidazole and meropenem. WGS showed that the molecular size of C. difficile was about 3.98-4.22Mb. The GC content was about 28.13-29.21%. More than 3000 CDSs were found and classified by COG functional annotation. There were 21-23 COG functional classifications, among which the genes of transcribed (K) were the maximum. KEGG annotation revealed that the metabolism genes in various pathways were the most. All isolates can be classified into 16 STs based on the MLST scheme, and ST 3 was the most common type, followed by ST 129 and ST 35 (4/36, 11.1%). Two biosynthetic gene clusters (BGCs) of secondary metabolites were annotated for each strain. 414 pathogenicity islands (PAIs) were predicted and 117 prophages were identified. 1718 CRISPR arrays, 3430 carbohydrate active enzyme genes, 14664 virility genes and 9276 antimicrobial resistance genes were found according to WGS. The macrolide and tetracycline resistance genes were found in most of these strains.
Conclusions
The toxins of the strains were mainly toxin A and toxin B. All isolates were sensitive to rifaximin. The resistance rates of rifampicin and vancomycin were low. All strains were resistant to ceftriaxone, ceftazidime and clindamycin. Rifaximin may be used as the primary treatment for nonrecurrent CDI in children. Biological functional genes such as energy, metabolism and transcription repair of C. difficile were abundant. The isolates were mainly ST 3 according to the MLST scheme.
{"title":"IDDF2023-ABS-0233 The study of molecular pathogenesis of pediatric clostridiodes difficile infection","authors":"Xiaolu Li, Rong Cao, Fangfei Xiao, Lin Ye, Xufei Wang, Yizhong Wang","doi":"10.1136/gutjnl-2023-iddf.209","DOIUrl":"https://doi.org/10.1136/gutjnl-2023-iddf.209","url":null,"abstract":"<h3>Background</h3> To evaluate the clinical characteristics and the molecular pathogenesis of <i>C. difficile</i>. <h3>Methods</h3> A total of 51 strains of <i>C. difficile</i> were collected from our hospital from 2014.10 to 2022.8. MICs for each strain against 11 antimicrobial agents were detected by the agar dilution method. Whole gene sequencing was performed on Illumina’s next-generation sequencing platform for 36<i> C. difficile</i> strains. <h3>Results</h3> 51 strains were isolated from 250 fecal samples. 44 strains were toxicogenic, and the detection rate of toxin A+B+ was 100%. Antimicrobial susceptibility testing showed that all isolates were sensitive to rifaximin. The resistance rates of rifampicin and vancomycin were low. All strains were resistant to ceftriaxone, ceftazidime and clindamycin, followed by erythromycin (84.31%), tetracycline, levofloxacin, metronidazole and meropenem. WGS showed that the molecular size of <i>C. difficile</i> was about 3.98-4.22Mb. The GC content was about 28.13-29.21%. More than 3000 CDSs were found and classified by COG functional annotation. There were 21-23 COG functional classifications, among which the genes of transcribed (K) were the maximum. KEGG annotation revealed that the metabolism genes in various pathways were the most. All isolates can be classified into 16 STs based on the MLST scheme, and ST 3 was the most common type, followed by ST 129 and ST 35 (4/36, 11.1%). Two biosynthetic gene clusters (BGCs) of secondary metabolites were annotated for each strain. 414 pathogenicity islands (PAIs) were predicted and 117 prophages were identified. 1718 CRISPR arrays, 3430 carbohydrate active enzyme genes, 14664 virility genes and 9276 antimicrobial resistance genes were found according to WGS. The macrolide and tetracycline resistance genes were found in most of these strains. <h3>Conclusions</h3> The toxins of the strains were mainly toxin A and toxin B. All isolates were sensitive to rifaximin. The resistance rates of rifampicin and vancomycin were low. All strains were resistant to ceftriaxone, ceftazidime and clindamycin. Rifaximin may be used as the primary treatment for nonrecurrent CDI in children. Biological functional genes such as energy, metabolism and transcription repair of <i>C. difficile</i> were abundant. The isolates were mainly ST 3 according to the MLST scheme.","PeriodicalId":10401,"journal":{"name":"Clinical Gastroenterology","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134904279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.1136/gutjnl-2023-iddf.190
Weihong Wang, Faming Zhang
{"title":"IDDF2023-ABS-0133 Gut microbiome components are associated with fecal microbiota transplantation related adverse events","authors":"Weihong Wang, Faming Zhang","doi":"10.1136/gutjnl-2023-iddf.190","DOIUrl":"https://doi.org/10.1136/gutjnl-2023-iddf.190","url":null,"abstract":"","PeriodicalId":10401,"journal":{"name":"Clinical Gastroenterology","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72930655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.1136/gutjnl-2023-iddf.194
Jack McNamara, J. Andrews, S. Connor, J. Pipicella, W. Wilson
{"title":"IDDF2023-ABS-0146 Disease and treatment factors influencing outcomes in fistulising crohn’s disease","authors":"Jack McNamara, J. Andrews, S. Connor, J. Pipicella, W. Wilson","doi":"10.1136/gutjnl-2023-iddf.194","DOIUrl":"https://doi.org/10.1136/gutjnl-2023-iddf.194","url":null,"abstract":"","PeriodicalId":10401,"journal":{"name":"Clinical Gastroenterology","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79642651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"IDDF2023-ABS-0087 A retrospective study of peroral endoscopic cardial constriction in the treatment of gastroesophageal reflux disease with esophageal hiatal hernia","authors":"Jui-yen Chen, Jiachuan Wu, Xiao-dong Chen, Li-fang Ye, Xiao-qiao Yang, Biao Liang","doi":"10.1136/gutjnl-2023-iddf.178","DOIUrl":"https://doi.org/10.1136/gutjnl-2023-iddf.178","url":null,"abstract":"","PeriodicalId":10401,"journal":{"name":"Clinical Gastroenterology","volume":"141 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76178405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：